

Press Release

Neubrandenburg, July 2, 2026

Speed Care Mineral Achieves Landmark Victory in Patent Dispute Against Teleflex

Speed Care Mineral GmbH, a leading specialist in innovative medical products for hemostasis, has achieved a significant legal victory. In a patent dispute lasting several years with the U.S. medical technology company Teleflex, the competent court ruled entirely in favor of Speed Care Mineral.

“We were confident in our technology from the very beginning,” says Managing Director Siegfried Kruse. “Our SpeedM® Emergency Hemostatic Dressing represents more than two decades of research in mineralogy and medical technology. The UPC’s decision reinforces our commitment to continuing on this path and making an innovative contribution to hemostasis in critical situations with SpeedM®.”

“This ruling is significant not only for Speed Care Mineral,” adds Ulf Pommerening. “It sends an important signal to the entire market. SpeedM® remains available. The UPC has invalidated the Teleflex patent to the extent asserted. This is the first time a court has confirmed that this patent does not preclude our halloysite technology for hemostasis. We are now intensifying our global production and sales activities and can participate in public tenders without restrictions.”

About Speed Care Mineral:

Speed Care Mineral has developed a production process that permanently and safely applies the hemostatic mineral halloysite to a non-woven cellulose matrix, ensuring that no minerals remain in the wound.

The SpeedM® product is a third-generation mineral hemostatic agent that combines performance, safety, control, and speed at a very high level.

Details of the decision:

On April 27, 2026, the Hamburg Local Chamber of the Unified Patent Court (UPC) announced its decision in the legal dispute between Teleflex Life Sciences II LLC (“Teleflex”) and Speed Care Mineral GmbH (“SCM”). This decision has been final since July 2, 2026.

- As early as the fall of 2024, Teleflex had unsuccessfully attempted to obtain an injunction against SCM in preliminary injunction proceedings (Case No. UPC_CFI_701/2024) based on Patent EP 2 077 811 B1, which relates to a clay-mineral-based hemostatic device. Teleflex’s motion was dismissed by a court order dated February 21, 2025, following an oral hearing, as the Local Chamber found that proof of infringement had not been established. Teleflex did not appeal the decision.
- At the same time, Teleflex continued to pursue its infringement claim in a parallel main action (UPC_CFI_685/2024). SCM also defended itself against this claim and, in turn, filed a counterclaim for nullity (UPC_CFI_157/2025).
- In response to SCM’s counterclaim for nullity, the Unified Patent Court declared the Teleflex patent EP 2 077 811 B1 null and void for the territories of Austria, Belgium, Denmark, Finland, France, Germany, Italy, the Netherlands, Portugal, and Sweden, to the extent of claims 1, 2, 3, 7, and 9 asserted by Teleflex.
- This corresponds to the scope of the patent infringement action that Teleflex had brought against SCM. The infringement action was dismissed.
- The court had already rejected a motion by Teleflex on June 17, 2025, seeking the disclosure of confidential technical specifications and manufacturing details regarding SpeedM®.

For further information or media inquiries, please contact:

Siegfried Kruse
Managing Director
Speed Care Mineral GmbH
info@speedcaremineral.de